Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most common reasons for the increase in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. Moreover, liver- associated death is approximately 10 times higher in patients with NAFLD than in common individuals. In theory, NAFLD is a kind of metabolic syndrome that manifests in the liver, and insulin resistance plays an important role in it. Therefore, drugs that improve insulin sensitivity may be effective for NAFLD.
Objective: The aim of this study was to evaluate the effect of metformin treatment on aminotransferase levels, metabolic parameters and body mass index in NAFLD patients via a meta-analysis of clinical trials.
Methods: A comprehensive search on PubMed, EMBASE, the Web of Science and the Cochrane Central Register of Controlled Trials was performed for randomized controlled trials (RCTs) on the effect of metformin treatment on aminotransferase levels, metabolic parameters and body mass index in NAFLD patients. Serum hepatic enzyme, lipid, glucose and insulin levels, homeostasis model assessment-insulin resistance (HOMA-IR) index and body mass index (BMI) at different follow-up points exhibited desirable outcomes. The final search was performed in January, 2021.
Results: In total, 10 RCTs with 459 patients were included. Compared with controls, metformin could effectively reduce serum fasting glucose and insulin levels and the HOMA-IR index in NAFLD patients at the 6-month follow-up. In addition, metformin could clearly reduce the serum ALT and HOMA-IR index at the 12-month follow-up. Although metformin was found to be effective in managing lipid metabolism and controlling BMI in NAFLD patients compared with that at baseline, the effect was similar to that in controls. In addition, the speed of metformin treatment seemed to be slower than that of controls.
Conclusion: Compared to the controls, metformin could effectively reduce the serum fasting glucose and insulin levels and the HOMA-IR index in NAFLD patients at the 6-month follow-up and ALT and the HOMA-IR index at the 12-month follow-up.
Keywords: Metformin, nonalcoholic fatty liver disease, aminotransferase, metabolic syndrome, body mass index, meta-analysis.
Current Pharmaceutical Design
Title:The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis
Volume: 27 Issue: 29
Author(s): Haibo Hu*, Junjie Wang, Xi Li, Lujun Shen, Danhe Shi and Juanjuan Meng
Affiliation:
- Department of Gastroenterology, Changzhi People’s Hospital, Changzhi,China
Keywords: Metformin, nonalcoholic fatty liver disease, aminotransferase, metabolic syndrome, body mass index, meta-analysis.
Abstract:
Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most common reasons for the increase in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. Moreover, liver- associated death is approximately 10 times higher in patients with NAFLD than in common individuals. In theory, NAFLD is a kind of metabolic syndrome that manifests in the liver, and insulin resistance plays an important role in it. Therefore, drugs that improve insulin sensitivity may be effective for NAFLD.
Objective: The aim of this study was to evaluate the effect of metformin treatment on aminotransferase levels, metabolic parameters and body mass index in NAFLD patients via a meta-analysis of clinical trials.
Methods: A comprehensive search on PubMed, EMBASE, the Web of Science and the Cochrane Central Register of Controlled Trials was performed for randomized controlled trials (RCTs) on the effect of metformin treatment on aminotransferase levels, metabolic parameters and body mass index in NAFLD patients. Serum hepatic enzyme, lipid, glucose and insulin levels, homeostasis model assessment-insulin resistance (HOMA-IR) index and body mass index (BMI) at different follow-up points exhibited desirable outcomes. The final search was performed in January, 2021.
Results: In total, 10 RCTs with 459 patients were included. Compared with controls, metformin could effectively reduce serum fasting glucose and insulin levels and the HOMA-IR index in NAFLD patients at the 6-month follow-up. In addition, metformin could clearly reduce the serum ALT and HOMA-IR index at the 12-month follow-up. Although metformin was found to be effective in managing lipid metabolism and controlling BMI in NAFLD patients compared with that at baseline, the effect was similar to that in controls. In addition, the speed of metformin treatment seemed to be slower than that of controls.
Conclusion: Compared to the controls, metformin could effectively reduce the serum fasting glucose and insulin levels and the HOMA-IR index in NAFLD patients at the 6-month follow-up and ALT and the HOMA-IR index at the 12-month follow-up.
Export Options
About this article
Cite this article as:
Hu Haibo *, Wang Junjie , Li Xi , Shen Lujun , Shi Danhe and Meng Juanjuan, The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis, Current Pharmaceutical Design 2021; 27 (29) . https://dx.doi.org/10.2174/1381612827666210315144821
DOI https://dx.doi.org/10.2174/1381612827666210315144821 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diagnosis and Prognosis of Fetal Cardiomyopathies: A Review
Current Pharmaceutical Design Crosstalk between Oxidative and Nitrosative Stress and Arterial Stiffness
Current Vascular Pharmacology The Adipose Tissue as a Source of Vasoactive Factors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Targeting Mitochondrial Biogenesis to Treat Insulin Resistance
Current Pharmaceutical Design A Review of Patents on Implantable Heart-Compression/Assist Devices and Systems
Recent Patents on Biomedical Engineering (Discontinued) Role of Statins in Diabetes Complications
Current Diabetes Reviews Statins and Thrombin
Current Drug Targets - Cardiovascular & Hematological Disorders Chymase as an Important Target for Preventing Complications of Metabolic Syndrome
Current Medicinal Chemistry Chest Pain in Children
Current Pediatric Reviews Use of Medication in Coronary Imaging by CT
Current Medical Imaging Technological Innovations in Magnetic Resonance for Early Detection of Cardiovascular Diseases
Current Pharmaceutical Design Therapeutic Implications of Superoxide Dismutase And Its Importance in Kinase Drug Discovery
Current Topics in Medicinal Chemistry BK Channel Modulators: A Comprehensive Overview
Current Medicinal Chemistry Oral Antiplatelet Agents and Bleeding Risk in Relation to Major Cardiovascular Surgery
Current Drug Safety Bv8-Prokineticins and their Receptors: Modulators of Pain
Current Pharmaceutical Biotechnology Editorial [Hot Topic Cardiovascular and Metabolic Diseases: from Mechanisms to Novel Therapeutical Implications Guest Editors: Attila Borbély and Pawel Petkow Dimitrow]
Current Pharmaceutical Biotechnology Evaluation of the Risk/Benefit Ratio of Old and New Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Selective Inhibitors of Inducible Nitric Oxide Synthase: Potential Agents for the Treatment of Inflammatory Diseases?
Current Topics in Medicinal Chemistry Consumption of Polyphenol Plants May Slow Aging and Associated Diseases
Current Pharmaceutical Design